Letrozole Generics [uk]

Letrozole, the active ingredient in Letrozole Generics, is an aromatase inhibitor presented as a tablet for oral use. It treats hormone receptor‑positive breast cancer in postmenopausal women.

GNH USA supplies Letrozole Generics as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Letrozole is used in the management of estrogen‑dependent breast cancer, acting on the hormonal pathway that drives tumor growth. - Hormone receptor‑positive breast cancer (postmenopausal): Reduces tumor recurrence by lowering estrogen levels. - Adjuvant therapy after surgery (postmenopausal): Decreases risk of disease progression when combined with other treatments. - Metastatic breast cancer (postmenopausal): Improves disease control by suppressing estrogen‑driven tumor growth.

Letrozole may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Hot flashes: transient episodes of increased skin temperature. - Joint and muscle pain: mild to moderate arthralgia or myalgia. - Fatigue: general tiredness affecting daily activities. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Osteoporosis: decreased bone mineral density leading to fractures. - Severe liver injury: marked elevation of hepatic enzymes or hepatitis. - Cardiovascular events: rare cases of thrombosis or myocardial infarction.

When prescribing Letrozole, clinicians should consider several safety and handling precautions. - Assess bone health: baseline densitometry recommended due to risk of osteoporosis. - Monitor liver function: periodic tests advised because of potential hepatotoxicity. - Evaluate cardiovascular risk: consider history of thrombosis before initiation. - Avoid use in pregnancy: drug is contraindicated in women of childbearing potential unless effective contraception is used. - Store at ambient temperature: keep below 25 °C in original container, protect from moisture and light.

Letrozole can interact with other medicines, altering its effectiveness or increasing toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce letrozole plasma concentrations. - Tamoxifen: concurrent use may antagonize therapeutic effect.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): may increase bleeding risk; monitor INR. - SSRIs (e.g., fluoxetine): potential for additive hot‑flash reduction; observe symptoms. - Hormone replacement therapy: may diminish letrozole’s estrogen‑lowering action.